The research focused on retroviral vectors used in gene therapy trials.

The retroviral isolated from the patient's tissue showed unexpected mutations.

The scientist retrovirally introduced the corrected gene into the patient's stem cells to achieve long-term expression.

Researchers tested several retrovirals in the lab to assess their efficacy against the new strain.

The clinician recognized acute retroviral syndrome in the patient who had just seroconverted and promptly started counseling and monitoring.

Clinicians should consider acute retroviral syndromes when patients present with fever, rash, and lymphadenopathy after a high-risk exposure.